Clinical Evidence: What the Published Trials Actually Show
Wegovy vs Mounjaro Weight Loss Results: Understanding the Clinical Evidence
When evaluating Wegovy versus Mounjaro for weight management, it's essential to examine the published clinical trial data objectively. Wegovy's efficacy has been demonstrated through the comprehensive STEP clinical programme, with the landmark STEP 1 trial showing approximately 15% average weight loss at 68 weeks when used alongside a reduced-calorie diet and increased physical activity. Mounjaro's SURMOUNT trials have shown their own distinct results, but comparing percentages directly isn't clinically appropriate due to different trial designs, patient populations, and endpoints. Both treatments represent evidence-based approaches to weight management, requiring prescription assessment and ongoing medical supervision.
The key difference in mechanisms helps explain why Wegovy vs Mounjaro discussions focus on individual suitability rather than declaring one superior. Wegovy works as a GLP-1 receptor agonist, mimicking natural satiety hormones, while Mounjaro functions as a dual GIP and GLP-1 receptor agonist. Your prescriber can evaluate which mechanism might align better with your medical history, current medications, and weight management goals during the clinical assessment process.
Wegovy vs Mounjaro Pricing: UK Prescription Costs Compared
Understanding the cost implications when choosing between Wegovy and Mounjaro helps inform your treatment decision. Wegovy pricing at EverydayMeds starts with the 0.25mg starter dose at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the maintenance 2.4mg dose (£209.99). New customers can apply discount code FIRST40 at checkout to reach these final prices, while returning customers use code DOSE25. Our bundle options provide supply convenience, such as the Intro Trio containing three progressive doses (0.25mg, 0.5mg, and 1mg) for £299.99.
Mounjaro pricing follows a different structure due to its distinct dosing schedule and pen design. Both Wegovy vs Mounjaro treatments require the same rigorous prescription process, including a 3-minute online clinical assessment followed by prescriber review within 3 working days (or 24 hours with express service). The total treatment cost depends on your individual dose escalation timeline and maintenance requirements, which your prescriber will determine based on your response and clinical needs.
STEP Trial Results: Wegovy vs Mounjaro Clinical Performance
The STEP clinical programme provides robust evidence for Wegovy's weight management efficacy across diverse patient populations. STEP 1 demonstrated approximately 15% average weight loss at 68 weeks, while STEP 3 achieved around 16% when combined with intensive behavioural therapy, as published by Wilding et al., NEJM, 2021. STEP 5 showed sustained results of approximately clinically studied weight loss maintained at 2 years, indicating long-term effectiveness when treatment continues.
When considering Wegovy vs Mounjaro trial evidence, it's important to note that direct percentage comparisons aren't clinically meaningful due to different trial methodologies. The recent SELECT cardiovascular outcomes trial showed Wegovy reduced major cardiovascular events by 20%, adding another dimension to treatment selection beyond weight loss alone. Both treatments require ongoing commitment alongside lifestyle modifications for optimal results.
How Wegovy Works vs Mounjaro: Mechanism Differences Explained
Understanding the mechanistic differences between Wegovy and Mounjaro helps explain why prescribers might recommend one over the other for specific patients. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural incretin hormone GLP-1, which promotes feelings of fullness and reduces appetite by acting on brain appetite centres. This mechanism helps patients feel satisfied with smaller meal portions and may reduce food cravings between meals. Mounjaro's tirzepatide works as a dual agonist, targeting both GIP and GLP-1 receptors simultaneously, creating a different physiological response. Both mechanisms require 4-week dose escalation periods to minimise gastrointestinal side effects and optimise tolerability.
Wegovy vs Mounjaro Ordering Process: UK Prescription Requirements
Obtaining either Wegovy or Mounjaro through EverydayMeds follows the same rigorous prescription process, ensuring appropriate clinical oversight for both treatments. The journey begins with a comprehensive 3-minute online clinical assessment covering your medical history, current medications, weight management goals, and previous treatment experiences. Our qualified prescribers review your assessment within 3 working days (or 24 hours with express service), determining suitability and appropriate starting doses based on MHRA licensing criteria. Once approved, your prescription is dispensed from our GPhC-registered pharmacy #9012878 and dispatched via next-day cold-chain delivery to maintain medication integrity. The temperature-controlled packaging ensures both Wegovy and Mounjaro reach you in optimal condition, ready for subcutaneous injection using the provided FlexTouch pen system.
Storage and Practical Considerations: Wegovy vs Mounjaro Handling
Practical storage differences between Wegovy and Mounjaro can influence treatment choice, particularly for patients who travel frequently or have variable schedules. Both medications require refrigeration between 2-8°C before first use, but Wegovy offers superior room temperature stability, remaining effective for up to 6 weeks below 30°C once removed from refrigeration. Mounjaro maintains stability for 21 days at room temperature, making Wegovy more suitable for extended travel or situations where refrigeration access is inconsistent. Both treatments use similar injection techniques with pre-filled pens, requiring once-weekly subcutaneous administration and following mandatory dose escalation schedules. The FlexTouch pen design for Wegovy and KwikPen design for Mounjaro both feature dose counters and safety mechanisms, though some patients express preferences for one pen style over another during treatment.
UK-Specific Wegovy vs Mounjaro Prescribing Considerations
Within the UK healthcare context, both Wegovy and Mounjaro are subject to MHRA licensing requirements and NICE guidance for weight management prescribing. Wegovy benefits from established NICE recommendation TA875, supporting its use within specialist weight management services, while Mounjaro's NICE evaluation continues to evolve. Both treatments require BMI ≥30 (or BMI ≥27 with weight-related comorbidities) for prescription eligibility, alongside commitment to reduced-calorie diet and increased physical activity programmes. The choice between Wegovy vs Mounjaro often depends on individual patient factors, including diabetes status, cardiovascular risk profile, and previous treatment responses.
NHS availability varies significantly across different Clinical Commissioning Groups, making private prescription through regulated online pharmacies like EverydayMeds an important access route for many patients. Both treatments carry the Black Triangle ▼ symbol indicating MHRA additional monitoring, requiring careful patient selection and ongoing clinical supervision throughout treatment duration.
Making Your Wegovy vs Mounjaro Decision: Next Steps
Both Wegovy and Mounjaro represent evidence-based approaches to prescription weight management, available through EverydayMeds following appropriate clinical assessment. Your prescriber can help determine which treatment aligns with your individual health profile, treatment goals, and practical considerations during the consultation process. Starting your journey requires completing the online clinical assessment, where you can indicate any preference between treatments while allowing clinical expertise to guide the final decision. New customers can use discount code FIRST40 at checkout, while returning customers apply DOSE25 to access our competitive pricing structure. Our clinical team provides ongoing support throughout your treatment journey, ensuring optimal outcomes and addressing any questions about your chosen therapy.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
